Dr. Ross is the author or co-author of over 50 publications, patents and presentations.
Selected
Publications
“A Selective Small Molecule NOP (ORL-1 receptor) Partial Agonist for the Treatment of Anxiety”
Ross TM, Battista K, Bignan GC, Brenneman DE, Connolly PJ, Liu J, Middleton SA, Orsini M, Reitz AB, Rosenthal DI, Scott MK, Vaidya AH
Bioorg. Med. Chem. Lett., 25, 602-606, 2015
“Enantioselective Synthesis of Decalin Structures with All-carbon Quaternary Centers via One-pot Sequential Cope/Rauhut-Currier Reaction”
Ross TM, Burke SJ, Malachowski WP
Tetrahedron Lett., 55, 4616-4618, 2014
“Discovery of RG7388, a Potent and Selective p53-MDM2 Inhibitor in Clinical Development”
Ding Q, Zhang Z, Liu JJ, Jiang N, Zhang J, Ross TM, Chu XJ, Barkovitz D, Podlanski FJ, Janson C, Tovar C, Filipovic ZM, Higgins B, Glenn K, Packman K, Vassilev L, Graves B,
J. Med. Chem., 56 (14), 5979-5983, 2013
Selected Patents
“Novel N-Substituted 5-Hydroxymethylpyrrolindines as Inhibitors of MDM2-p53 Interactions”
Liu JJ, Ross TM, Hoffmann-La Roche
U.S. Patent Appl. Publ., 20120149660 (June 14, 2012)
“N-Substituted-pyrrolidines as Inhibitors of MDM2-p-53 Interactions”
Bartkovitz DJ, Chu X-J, Liu JJ, Ross TM, Zhang Z, Hoffmann-La Roche
U.S. Patent #8,017,607 (September 13, 2011)
“Hydroxy alkyl substituted 1,3,8- triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders”
Battista K, Bignan, G., Connolly PJ, Ross TM, Johnson & Johnson
U.S. Patents 8,778,956 (July 15, 2014) and 7,582, 649 (September 1, 2009)